Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

NCT03872661 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Stage III

Interventions

DRUG: IBI308
DRUG: Bevacizumab
DRUG: Pemetrexed
DRUG: Carboplatin
PROCEDURE: Thoracic surgery

Sponsor

Sun Yat-sen University